Jubilant Pharmova Limited has informed the Exchange regarding Board meeting held on Jun 12, 2025.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Smallcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Pharmova's Board has approved the sale and transfer of its Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited (JBL), its wholly-owned subsidiary, on a slump sale basis. The API business contributed Rs. 609 crore in turnover (8.35% of consolidated revenue) and had a net worth of Rs. 666.5 crore (10.68% of consolidated net worth) in FY25. The purchase consideration will be based on the book value of assets and liabilities, and will be discharged mainly through the issuance of shares, not cash. The deal is expected to complete by September 1, 2025, subject to lender and shareholder approvals. The rationale is to combine drug discovery and CDMO API operations under one entity, creating an end-to-end CRDMO platform under the 'Jubilant Biosys' brand to improve operational efficiency and asset utilisation.
Since the transfer is to a wholly-owned subsidiary with no change in ultimate economic interest for shareholders, this is largely an internal restructuring. Shareholders are unlikely to see a major stock price reaction, but the move signals sharper focus on building a unified CRDMO platform with a Vision 2030 target of 2x revenue growth and EBITDA margins above 15% for the API business.